Nonetheless, this study is a trial-level meta-analysis and cannot provide definitive evidence on the lack of AF-preventive benefit of SGLT2 inhibitors in patients with HFmEF or HFpEF. The gene discussed is SLC5A2; the disease is atrial fibrillation.